There have been big changes in the aesthetic corporate world recently. With heavy hitters from
Josh Levine, former Mentor CEO, resigned last week. Levine joined
Following the January 2009 acquisition of
Robert Grant, the former Allergan Vice President, resigned last week to take over the presidency of Bausch and Lomb Surgical Division, an Aliso Viejo-based eye surgery business. Grant has spent almost a lifetime in the aesthetics business and is quite possibly moving to maybe a safer, but surely not as exciting, endeavor. Under Grant’s leadership since 2006, Allergan Medical amassed an all-star product lineup that includes Botox Cosmetic ®, JuvĂ©derm ®, the Lap-Band ® surgical weight loss device and Latisse ®.
Perhaps Grant made his decision to join the B & L team based on his experience as an independent board director at Acufocus, Inc., a Carlyle Group and Versant Ventures-backed clinical stage ophthalmic device company. This appears to be a lateral move for Grant, however, he has not been assigned a seat on the Board of Directors of B & L. Is his move indicative of something internally up at our leading aesthetics company Allergan, or Grant's vision of an increasingly regulated, and maybe less attractive, industry to come? Stay tuned here!
Finally, Joe Cooper, the former VP of Corporate and Product Development at Medicis, has also resigned. Similar to Levine, Cooper had been with Medicis since 1996. Cooper has served as Executive Vice President, Corporate and Product Development since July 2006. Prior to joining the Medicis executive team, he held management positions with Schein Pharmaceuticals, Inc. and G.D. Searle
According to BusinessWeek, Cooper "has decided to pursue career opportunities outside of Medicis." This is not the first time Cooper left Medicis for greener pastures. Earlier in the decade he went off to run a start up. Cooper returned to lead the way in his business development role with important strategic investments in Revance ®, Dysport ® and Liposonix ® for Medicis.
There are certainly big shoes to fill in the aesthetic industry and hopefully Allergan,
No comments:
Post a Comment